Mateusz Opyrchal

11PUBLICATIONS
64CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersBasic pharmacologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.

Tim Kong, Alex Mabry, Maureen Highkin

|Aug 22, 2025
Reprogramming intratumoral Treg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy.

Yujing Li, Naresh Singh, Chuanpeng Dong

|Sep 18, 2024
Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity.

Ateeq M Khaliq, Meenakshi Rajamohan, Omer Saeed

|Mar 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

Filip Janku, Grace M Choong, Mateusz Opyrchal

|Feb 24, 2024
Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients.

Rylee Ann Poole, Qingfei Wang, Alo Ray

|Jun 02, 2023
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.

Whitney L Hensing, Lorenzo Gerratana, Katherine Clifton

Pageof 2

Frequent Collaborators

3 joint publications

Kazuaki Takabe

3 joint publications

Foluso O Ademuyiwa

2 joint publications

Austin Miller

2 joint publications

Ajay Dhakal